F M Investments LLC Makes New Investment in GeneDx Holdings Corp. (NASDAQ:WGS)

F M Investments LLC purchased a new position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,469 shares of the company's stock, valued at approximately $574,000.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in GeneDx by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company's stock worth $77,337,000 after acquiring an additional 156,768 shares in the last quarter. William Blair Investment Management LLC bought a new stake in GeneDx in the fourth quarter worth $51,496,000. Geode Capital Management LLC grew its stake in shares of GeneDx by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 382,350 shares of the company's stock worth $29,396,000 after acquiring an additional 4,719 shares during the last quarter. State Street Corp increased its holdings in shares of GeneDx by 18.3% during the third quarter. State Street Corp now owns 314,914 shares of the company's stock valued at $13,365,000 after acquiring an additional 48,735 shares in the last quarter. Finally, Zweig DiMenna Associates LLC bought a new position in GeneDx in the 4th quarter worth about $23,788,000. 61.72% of the stock is owned by institutional investors.

GeneDx Stock Performance

GeneDx stock traded down $2.80 during mid-day trading on Thursday, reaching $95.49. 315,621 shares of the stock traded hands, compared to its average volume of 677,443. GeneDx Holdings Corp. has a 12-month low of $8.63 and a 12-month high of $115.60. The stock has a market capitalization of $2.68 billion, a PE ratio of -48.73 and a beta of 1.93. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The business's 50-day moving average is $92.69 and its 200-day moving average is $79.08.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. As a group, sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

WGS has been the topic of several analyst reports. The Goldman Sachs Group upped their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen increased their price objective on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $72.33.

Insiders Place Their Bets

In other news, CEO Katherine Stueland sold 46,594 shares of the company's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $89.62, for a total value of $4,175,754.28. Following the completion of the transaction, the chief executive officer now owns 1,720 shares of the company's stock, valued at $154,146.40. This represents a 96.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kevin Feeley sold 3,749 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $362,565.79. Following the completion of the transaction, the chief financial officer now owns 8,492 shares of the company's stock, valued at $821,261.32. The trade was a 30.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 138,780 shares of company stock worth $12,907,437. Company insiders own 27.30% of the company's stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.